Haleon has the GF Score of 70, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Haleon
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Haleon (NYSE:HLN) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Haleon GF Score Related Terms
HLN vs ZTS, UTHR, VTRS: GF Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleon GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haleon's GF Score distribution charts can be found below:
* The bar in red indicates where Haleon's GF Score falls into.
Haleon (HLN) has a GF Score of 70 as of Jul. 09, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Haleon and its competitors. This is 159% above median its historical median of 27.00. Over the past decade, Haleon's GF Score has ranged from 20.00 to 84.00.
Is Haleon's GF Score too high?
Haleon's current GF Score of 70 is 159% above median its 10-year median of 27.00. Over the past 10 years, this metric has ranged from a low of 20.00 to a high of 84.00. Overall, Haleon has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Haleon's GF Score compare to ZTS and UTHR?
Haleon's GF Score of 70 can be compared against companies in the Drug Manufacturers industry. Historically, Haleon's own GF Score has ranged from 20.00 to 84.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Haleon and its competitors. Haleon's current GF Score is 70, which is 159% above median its own 10-year median of 27.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleon stock overvalued right now?
Based on GuruFocus' analysis, Haleon (HLN) is currently considered Fairly Valued. The stock's GF Value™ is $9.76, compared to a current price of $9.75 — trading 0.1% below its estimated fair value. The current GF Score is 70, which is 159% above median its 10-year median of 27.00. Haleon's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Haleon (HLN), the current GF Score is 70 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleon (HLN) Overvalued in 2026?
Based on GuruFocus' analysis, Haleon stock appears to be undervalued.
The current stock price of $9.75 is trading 0.1% below its estimated GF Value™ of $9.76.
GuruFocus considers Haleon to be Fairly Valued.
Key valuation signals for HLN:
GF Score: 70 (159% above median its 10-year median of 27.00)
GF Value™: $9.76 vs. price of $9.75 (0.1% below fair value)
No single metric tells the full story. See the HLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
70GF Score
Get the complete analysis for HLN
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HLN has been successfully added to your 